ScholarLens Back to search
2004•Hospital MedicineRequires access

Combating mortality from severe sepsis

S. Ridley

Open publisher page 0 citations

Abstract

Thousands of patients suffering from severe sepsis are set to benefit from the publication of the National Institute for Clinical Excellence (NICE) guidelines recommending the use of Xigris (drotrecogin alfa (activated), Eli Lilly & Company Ltd, Basingstoke). Drotrecogin alfa (activated) is the only drug specifically designed to treat severe sepsis and has been recommended for use in adult patients who have severe sepsis that has resulted in multiple organ failure and who are being provided with optimum intensive care support (NICE, 2004).

About this research paper

What this paper is about

Thousands of patients suffering from severe sepsis are set to benefit from the publication of the National Institute for Clinical Excellence (NICE) guidelines recommending the use of Xigris (drotrecogin alfa (activated), Eli Lilly & Company Ltd, Basingstoke). Drotrecogin alfa (activated) is the only drug specifically designed to treat severe sepsis and has been recommended for use in adult patients who have severe sepsis that has resulted in multiple organ failure and who are being provided with optimum intensive care support (NICE, 2004).

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Thousands of patients suffering from severe sepsis are set to benefit from the publication of the National Institute for Clinical Excellence (NICE) guidelines recommending the use of Xigris (drotrecogin alfa (activated), Eli Lilly & Company Ltd, Basingstoke). Drotrecogin alfa (activated) is the only drug specifically designed to treat severe sepsis and has been recommended for use in adult patients who have severe sepsis that has resulted in multiple organ failure and who are being provided with optimum intensive care support (NICE, 2004).

Key concepts: Drotrecogin alfa, Medicine, Nice, Sepsis, Severe sepsis, Intensive care medicine, Excellence, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Combating mortality from severe sepsis — Research Paper | ScholarLens